文献速递药物不良反应与药物警戒

利用机器学习促进药物不良反应个例因果关系评估

Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
PubMed 文献 · Drug Saf · 2022-05-17

本研究基于公司上市后数据库中的5万例标注个例安全报告(ICSR),融合时间合理性、科学有效性及混杂性等补充特征,构建贝叶斯网络模型预测药物-事件对的因果关系;在2万例独立时间相邻数据集上,模型AUC为0.924(95%CI 0.922-0.927),灵敏度0.900(95%CI 0.896-0.904),阳性预测值0.778(95%CI 0.773-0.783),优于全局内省临床判断。

要点

  • 贝叶斯网络模型可高精度预测ICSR中药物-事件对的因果关系。
  • 模型在独立数据集中AUC达0.924,灵敏度0.900,PPV 0.778。
  • 该建模框架有望改进药物警戒中的安全性决策。

核心结论

  • 对ICSR因果关系进行稳健的概率建模是可行的,所开发模型的方法可作为此类评估的框架,从而改进安全性决策。

研究设计与样本

  • 研究使用公司上市后数据库中5万例标注的 solicited ICSR,构建贝叶斯网络模型预测药物-事件对因果关系。
  • 模型拓扑由内部开发的ICSR因果关系决策支持工具驱动。
  • 在时间相邻区间的2万例独立数据集上评估模型性能,未进行外部验证。

主要发现

  • 模型预测药物-事件对因果关系评估的AUC为0.924(95%CI 0.922-0.927),对比基于全局内省的临床判断。
  • 模型灵敏度为0.900(95%CI 0.896-0.904),阳性预测值为0.778(95%CI 0.773-0.783)。

关键数值与推荐

  • 模型性能评估指标包括灵敏度、阳性预测值(PPV)和受试者工作特征曲线下面积(AUC)。
  • 数据富集了来自外部和内部数据源的新补充特征,旨在捕获时间合理性、科学有效性和混杂性等维度。

临床怎么用

  • 该模型可作为药物警戒个例因果关系评估的辅助工具,支持安全性决策。

局限性

  • 由于缺乏公开可用的带因果关系评估的ICSR药物-事件对,未进行外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Causality assessment of individual case safety reports (ICSRs) is an important step in pharmacovigilance case-level review and aims to establish a position on whether a patient's exposure to a drug is causally related to the patient experiencing an untoward adverse event. There are many different approaches for case causality adjudication, including the use of expert opinions and algorithmic frameworks; however, a great deal of variability exists between assessment methods, products, therapeutic classes, individual physicians, change of process and conventions over time, and other factors. OBJECTIVE: The objective of this study was to develop a machine learning-based model that can predict the likelihood of a causal association of an observed drug-reaction combination in an ICSR. METHODS: In this study, we used a set of annotated solicited ICSRs (50K cases) from a company post-marketing database. These data were enriched with novel supplementary features from external and internal data sources that aim to capture facets such as temporal plausibility, scientific validity, and confoundedness that have been shown to contribute to causality adjudication. Using these features, we constructed a Bayesian network (BN) model to predict drug-event pair causality assessment. BN topology was driven by an internally developed ICSR causality decision support tool. Performance of the model was evaluated through examination of sensitivity, positive predictive value (PPV), and the area under the receiver operating characteristic curve (AUC) on an independent set of data from a temporally adjacent interval (20K cases). No external validation was performed because of a lack of publicly available ICSRs with causality assessments for drug-event pairs. RESULTS: The model demonstrated high performance in predicting the causality assessment of drug-event pairs compared with clinical judgment using global introspection (AUC 0.924; 95% confidence interval [CI] 0.922-0.927). The sensitivity of the model was 0.900 (95% CI 0.896-0.904), and the PPV of the model was 0.778 (95% CI 0.773-0.783). CONCLUSION: These results show that robust probabilistic modeling of ICSR causality is feasible, and the approach used in the development of the model can serve as a framework for such causality assessments, leading to improvements in safety decision making.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Cherkas Y, Ide J, van Stekelenborg J, et al. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions. Drug Saf. 2022. PMID: 35579819. doi:10.1007/s40264-022-01163-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。